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Abstract: Fragile X Syndrome (FXS) is the most common cause of inherited intellectual disability 
with prevalence rates estimated to be 1:5,000 in males and 1:8,000 in females. The increase of 
>200 Cytosine Guanine Guanine (CGG) repeats in the 5’ untranslated region of the Fragile X Men-
tal Retardation 1 (FMR1) gene results in transcriptional silencing on the FMR1 gene with a subse-
quent reduction or absence of fragile X mental retardation protein (FMRP), an RNA binding pro-
tein involved in the maturation and elimination of synapses. In addition to intellectual disability, 
common features of FXS are behavioral problems, autism, language deficits and atypical physical 
features. There are still no currently approved curative therapies for FXS, and clinical management 
continues to focus on symptomatic treatment of comorbid behaviors and psychiatric problems. 
Here we discuss several treatments that target the neurobiological pathway abnormal in FXS. These 
medications are clinically available at present and the data suggest that these medications can be 
helpful for those with FXS. 
Keywords: Fragile X syndrome, targeted treatment, sertraline, metformin, cannabidiol, acamprosate, lovastatin, minocycline. 
1. INTRODUCTION 
 Fragile X Syndrome (FXS) is the most common cause of 
inherited intellectual disability with prevalence rates esti-
mated to be 1:5,000 in males and 1:8,000 in females [1]. 
Individuals with 55 and 200 CGG repeats carry the premuta-
tion, which results in excessive transcription of the FMR1 
gene, but are usually not intellectually impaired. An increase 
of >200 CGG repeats gives rise to the full mutation and 
FXS. The full mutation results in transcriptional silencing of 
the FMR1 gene with a subsequent reduction or absence of 
fragile X mental retardation protein (FMRP), an RNA bind-
ing protein involved in the maturation and elimination of 
synapses. FMRP is important to dendritic maturity and syn-
aptic plasticity, and its reduced levels, therefore, lead to in-
tellectual impairment and FXS [2, 3].  
 Physical features have been described but are often non-
specific, making diagnostic testing based on alterations 
found in the FMR1 gene essential for the diagnosis of FXS. 
Common physical and medical features in FXS include  
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increased risk for chronic otitis media, esotropia, hyperex-
tensible finger joints, long face, prominent ears, high arched 
palate, low muscle tone, seizures (occurring in 16% of pa-
tients with FXS) and macroorchidism with puberty [4]. As 
FXS is an X-linked disorder, the symptoms manifest mark-
edly in males, who commonly present with moderate to se-
vere cognitive impairment. Females have two X chromo-
somes with variable activation ratios and are thus generally 
less affected, presenting with a spectrum of impairments 
from mild learning difficulties to intellectual disabilities [5]. 
The behavioral phenotype involves poor eye contact, exces-
sive shyness, anxiety, hand flapping, hand biting, aggression, 
tactile defensiveness, attention deficits, hyperactivity, impul-
sivity, hyperarousal to sensory stimuli, and autism spectrum 
disorder [6]. These symptoms are hypothesized to be caused 
by an altered balance in excitatory and inhibitory neuro-
transmission and by the absence of FMRP’s effect on synap-
tic plasticity and activity-dependent protein translation [7].  
 Pharmacological approaches have comprised the focus of 
treatment due to the biological cause of FXS. However, no 
currently approved curative therapies exist, and clinical 
management continues to focus on symptomatic treatment of 
comorbid behaviors and psychiatric problems. There have 
been several clinical trials in FXS, as well as multiple recent 
reviews thereof [4, 8, 9]. Notably failed trials in FXS include 
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the mGluR5 antagonists [10, 11]. These trials demonstrated a 
high rate of placebo response and did not involve quantita-
tive outcome measures that could directly assess the brain’s 
response to treatment to give unbiased results. Improved 
outcome measures are now in place for most newer clinical 
trials [4] to address these concerns. Lately, increasing em-
phasis on trials in young children with FXS reflects a recent 
effort to influence brain structure and development early on. 
For instance, the mGluR5 antagonist AFQ056 is now being 
studied in children 3 to 6 years old in a randomized con-
trolled trial that also involves intensive Parent Implemented 
Language Intervention (PILI) with a speech and language 
therapist twice weekly via video call (NCT02920892). 
 Here we discuss several medications that are currently 
available for off-label treatment of FXS, along with the data 
that support their therapeutic potential. While many other 
medications such as stimulants, alpha agonists, and atypical 
antipsychotics can also be used effectively to treat behavior 
problems in FXS, this discussion will be limited to modula-
tors of the abnormal neurobiological pathways in FXS where 
there is evidence that the abnormalities are at least partially 
reversed. [6]. The term targeted treatment was originally 
introduced to describe molecular treatment in cancer; it has 
been adopted by other areas of research to elucidate develop-
ing treatment modalities targeting specific abnormal path-
ways, in our case in FXS. 
2. CURRENTLY AVAILABLE TARGETED TREAT-
MENTS FOR FRAGILE X SYNDROME 
2.1. Sertraline 
 Sertraline, a selective serotonin reuptake inhibitor 
(SSRI), is widely used to treat anxiety in patients with FXS, 
often starting in the second or third year of life as symptoms 
emerge. There is a deficit in serotonin production in the 
brains of young children with autism [12, 13], and me-
tabolomic studies of lymphoblastoid lines of all types of 
ASD, including those with FXS, demonstrate down-
regulation of the enzymes leading to serotonin production 
from tryptophan [14]. Sertraline may therefore be considered 
a targeted treatment for FXS. 
 A retrospective study of language development using the 
Mullen Scales of Early Learning (MSEL) demonstrated that 
the trajectory of both receptive and expressive language de-
velopment was significantly improved in young children 
with FXS between ages 16 to 60 months who received low-
dose sertraline (2.5 to 5.0 mg per day) compared to those 
who did not receive sertraline [15]. Subsequently, a con-
trolled trial of low-dose sertraline was carried out in 57 chil-
dren ages 2 to 6 years with FXS, 60% of whom had comor-
bid ASD [16]. Although the primary outcome measures of 
expressive language MSEL age equivalent score and the 
Clinical Global Impression-Improvement (CGI-I) did not 
show efficacy, there was a significant improvement in the 
secondary measures, including the fine motor and visual 
perception scales and the composite T score sum on the 
MSEL, in those treated with sertraline versus placebo. In a 
post hoc analysis, among 60% of patients with comorbid 
ASD, there was a significant improvement in the expressive 
language MSEL scale [16]. Furthermore, of the 22 patients 
able to carry out the Passive Viewing Eye Tracking (PVET) 
task at baseline and follow-up, there was a significant im-
provement in the measure of receptive language on this task 
when the study patient was on sertraline compared to pla-
cebo [17]. Notably, in these children, the receptive language 
MSEL scale did not improve, suggesting that the PVET task 
was able to detect receptive language benefits with higher 
sensitivity than other measures. Sertraline is now often used 
to both treat anxiety and to enhance early development in 
children with FXS. 
2.2. Metformin 
 Metformin, a biguanide antihyperglycemic medication 
utilized most commonly for type 2 diabetes and weight loss, 
is derived from galegine, which is a natural product isolated 
from the plant Galega officinalis. This plant was used in 
herbal medicine in medieval Europe and by the ancient 
Egyptians [18]. In the 1920s, metformin was first synthe-
sized and tested, but its clinical use as an antidiabetic drug 
began in the 1950s [19, 20]. Metformin became available in 
the United States in 1995. Throughout metformin’s 60 years 
of clinical use, there have been thousands of studies regard-
ing its varied mechanisms of action [18]. Before molecular 
studies with metformin were possible in the current era, this 
medication was established as a safe and effective therapy 
for diabetes mellitus type 2 through clinical studies alone 
[21, 22].  
 After oral dosing in humans, approximately 70 to 80% of 
metformin's dose is absorbed in the small intestine (duode-
num and jejunum) [23]. The mean peak plasma concentra-
tion (Cmax) after an oral dose occurs at about 2 hours. When 
metformin is used in clinical doses, steady-state plasma con-
centrations in the low micromolar range (< 1µg/mL) are 
reached between 24 and 48 hours. Metformin does not bind 
to plasma proteins and crosses the blood-brain barrier 
(BBB), with higher concentrations found in plasma than in 
the brain after acute and chronic administration [24]. There 
are no metabolites of metformin, and unchanged metformin 
is excreted in urine (approximately 90% of the absorbed 
drug) within 24 hours of ingestion [23]. Creatine clearance is 
3.5 times lower than the clearance of metformin, which indi-
cates that tubular secretion is the major route of metformin 
elimination, and the renal uptake of metformin is mediated 
by organic cation transporter 2 (OCT2); it does not undergo 
hepatic metabolism nor biliary excretion [23]. The half-life 
(T1/2) of metformin is approximately 4-5 hours [23]. Unab-
sorbed metformin accumulates in the gut mucosa of the dis-
tal small intestine at a concentration 30- to 300-fold greater 
than in the plasma and is ultimately eliminated in feces [21]. 
 Metformin is now the most widely prescribed antidia-
betic agent in the management of diabetes mellitus type 2 
worldwide. The drug employs several mechanisms of lower-
ing glucose, with the primary effect of reduction of hepatic 
glucose production, or gluconeogenesis. The uptake of met-
formin into hepatocytes is primarily mediated by OCT1 [25, 
26]. In addition, it is well-known that metformin also has 
pleiotropic effects, including regulation of lipid metabolism 
(reduction of plasma triglycerides by 15 to 20%), cardiopro-
tection, anticancer activity, and decrease of body weight and 
food intake. The mechanism of action is dependent on the 
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dose and duration of treatment with clear differences be-
tween acute and chronic administration of the drug. In gen-
eral, metformin's mechanism of action includes both AMP-
activated protein kinase (AMPK)-dependent and AMPK-
independent pathways [18, 27]. Several mechanisms are re-
sponsible for AMPK-dependent impairment of mammalian 
target of rapamycin complex 1 (mTORC1) pathway activity. 
Furthermore, metformin has an inhibitory effect on the mito-
gen-activated protein kinases (MAPK) pathway. Although 
this effect of metformin was investigated in different in vitro 
models (including bladder, pancreatic and ovarian cancer), 
the exact mechanism of MAPK inhibition remains unclear 
[20, 28].  
 After over 6 decades of clinical experience with met-
formin, its short- and long-term side effects are well charac-
terized [21]. Gastrointestinal side effects (diarrhea, abdomi-
nal discomfort, nausea, metallic taste, and anorexia) occur in 
up to 20% of patients and can be minimized by taking the 
medication with or after meals and by starting at a low dose 
and slowly increasing to a maximum tolerated dose [25]. If 
necessary, the extended-release preparation of metformin 
could be administrated, as this preparation has fewer gastro-
intestinal side effects [25]. Lactic acidosis is typical of some 
other biguanides such as phenformin and buformin, which 
were removed from the market in the 1970s in most coun-
tries due to unacceptable rates thereof; in contrast, lactic aci-
dosis is an extremely rare side effect of metformin [26]. 
However, this condition is more likely to occur during severe 
illness or surgery, so temporary discontinuation of met-
formin treatment during such episodes is recommended [25, 
26]. 
 Preclinical studies have demonstrated that metformin 
ameliorates core deficits in animal models of FXS. Recently, 
Gantois and colleagues (2017) showed that metformin cor-
rected many phenotypic deficits [social deficit, repetitive 
behavior, macroorchidism, aberrant dendritic spine mor-
phology, and exaggerated long-term depression of synaptic 
transmission] in the adult FXS mouse model. Wild-type 
(WT) and FMR1−/y mice aged between 8 and 12 weeks 
were used in this investigation. Metformin, at a dose of 200 
mg per kg body weight per day, was administrated intraperi-
toneally for 10 days. They hypothesized that chronic met-
formin treatment corrected the enhanced Raf–MEK–ERK 
signaling and matrix metalloproteinase 9 (MMP-9) over-
expression in FMR1−/y mice [29]. MMP-9 is responsible for 
the degradation of the components of the extracellular ma-
trix, including proteins that are important for synaptic func-
tion and maturation, which have been implicated in FXS and 
ASD [30-32]. Hyperactivation of mTORC1 and extracellu-
lar-signal-regulated kinase (ERK) signaling pathways is pre-
sent in the brains of humans and mice models with FXS due 
to the loss of FMRP [33]. Finally, according to results ob-
tained from the mouse model of FXS, it seems that the ob-
served phenotypic rescue by metformin is selectively medi-
ated via ERK down-regulation and normalization of MMP-9 
expression in the brain [29]. Similarly, data obtained on the 
Drosophila melanogaster FX model, which is based on loss 
of dfmr1 function, demonstrated that metformin treatment 
corrected circadian and cognitive deficits [34]. In this study, 
Monyak and colleagues (2017) documented that insulin sig-
naling (IS) is increased in the brains of the Drosophila mela-
nogaster FX model and that treatment with metformin re-
duced IS, leading to improvements in memory and circadian 
rhythm defects [34].  
 The first clinical data of metformin's efficacy in FXS was 
obtained in 2017 [35]. Seven patients with FXS were treated 
clinically with metformin for at least 6 months. Almost all of 
these patients were prescribed metformin for obesity or 
treatment of type 2 diabetes and were additionally observed 
for behavior and metabolic improvements. The patients with 
FXS not only had improved weight and eating behavior but 
also experienced positive behavioral changes in areas such as 
irritability, social avoidance and aggression. Anecdotally, the 
parents and family members commented on language im-
provements. Metformin was well tolerated in all patients, 
even in a 4-year old child [35]. Subsequently, the first ran-
domized, placebo-controlled trial of metformin to further 
assess safety and benefits in the areas of language/cognition, 
eating, and overall behavior was initiated. The study includes 
subjects from 6 to 25 years with FXS randomized to placebo 
or metformin over a 4-month period and is taking place at 
the MIND Institute at University of California, Davis Health 
System (NCT03479476). Identical trials are commencing at 
the University of Alberta in Edmonton and at St Justine 
Hospital in Montreal, to maximize analytical power to de-
termine efficacy. The study results are expected by 2022. All 
in all, from a molecular perspective of looking at the meta-
bolic effects and signaling pathways, as well as from a clini-
cal vantage considering the data regarding metformin’s bene-
fit in FXS, this medication appears to be a strong candidate 
for a new targeted treatment for FXS. 
2.3. Cannabidiol (CBD) 
 The clinical use of CBD has decades of research support-
ing its effects for a variety of clinical problems. It has been 
proven beneficial in the treatment of inflammation [36-38], 
ameliorating pain in autoimmune diseases [39], controlling 
the urge to smoke in nicotine addiction [40], and even pro-
viding neuroprotection that may be useful to prevent glau-
coma and retinal neurodegenerative diseases [41]. The neu-
roprotective potential of CBD, based on the combination of 
its anti-inflammatory and antioxidant properties, showed 
certain benefits on the progression of striatal deterioration 
and proved highly effective in attenuating clasping behavior 
in the animal model of Huntington disease [42]; however, 
CBD did not show clinical improvement in humans with 
Huntington’s disease [43, 44]. On the other hand, CBD may 
be able to improve general Parkinsonism in Parkinson’s dis-
ease patients with no psychiatric comorbidities [45]. The 
therapeutic role of CBD in neuropsychiatric disorders has 
also been broadly studied. Crippa and colleagues have de-
scribed the anxiolytic effects of CBD in generalized social 
anxiety disorder and its use in facilitating habituation of an-
ticipatory anxiety [46-48]; other authors have reported that 
individuals taking CBD experience a reduction in anxiety, 
cognitive impairment, and discomfort during public speaking 
and performance [49, 50]. Furthermore, CBD is considered 
to have antipsychotic effects and may be useful to treat 
schizophrenia [51-54].  
 The anticonvulsant effects of CBD are the most studied 
to date; based on findings of recent controlled clinical trials, 
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the use of CBD has now been FDA-approved for the treat-
ment of resistant epilepsy in Dravet and Lennox-Gastaut 
syndromes in children and adolescents [55-58]. 
 Seizures and anxiety disorders are reported in approxi-
mately 20% and more than 80% of males with FXS respec-
tively [59, 60], making CBD a promising treatment to ad-
dress both comorbidities in FXS. Furthermore, the mGluR 
theory of fragile X [61] is based on the knowledge that 
FMRP is synthesized in response to mGluR activation, but 
FMRP inhibits this mGluR pathway [62]. Thus, it is hy-
pothesized that most of the features of FXS, including epi-
lepsy and cognitive impairment, are consequences of upregu-
lation of Gp1 mGluR-dependent protein synthesis in the ab-
sence of the inhibition of FMRP in FXS [61]. Gp1 mGluR 
activation can mobilize endocannabinoids (eCBs), increasing 
excitability. In 2010, Zhang and colleagues reported consis-
tent results on Fmr1 KO mice models, revealing increased 
neuronal excitability mediated by eCBs compared to WT 
mice; this alteration is believed to be a factor contributing to 
the cognitive dysfunctions associated with FXS [63]. As 
such, the endocannabinoid system thence became a promis-
ing target for intervention in FXS. Further controlled trials in 
children and adults with FXS are recommended to better 
understand the efficacy and tolerability of CBD in the treat-
ment of anxiety, seizures, and cognition in FXS. 
 In their review, Bergamaschi and colleagues, concluded 
that the controlled use of CBD may be safe in humans and 
animals regardless of the route of administration, even with 
chronic use and high doses up to 1,500 mg/day [64]. Recent 
studies have also found CBD to lack abuse potential [65] and 
have confirmed its safety and tolerability profiles via clinical 
trials [43, 45, 66]. Sultan and colleagues additionally con-
cluded that acute and chronic administration of CBD had no 
effect on hemodynamics in vivo under controlled conditions; 
however, its use reduced blood pressure and heart rate under 
stressful conditions [67]. A Phase 2 open-label trial of a 
CBD transdermal gel in children with FXS was carried out in 
Australia with 20 children and demonstrated efficacy in re-
ducing anxiety and improving other behavioral measures 
[68]. Currently, a phase 3 randomized double-blind con-
trolled trial is being conducted at multiple sites in Australia 
and the United States to assess the efficacy of this CBD 
transdermal gel used twice a day on the skin (CONNECT-
FX; NCT03614663). In many countries, CBD is legally sold 
at marijuana stores or through the internet and is thus avail-
able for clinical use. 
2.4. Acamprosate 
 Acamprosate, a drug approved for the maintenance of 
abstinence from alcohol, has recently been the focus of re-
search due to its potential pleiotropic effects impacting glu-
tamate and GABA neurotransmission. Its exact mechanism 
of action remains incompletely understood but may include 
effects on multiple receptors with the implication of potential 
mGluR5 antagonism [69, 70]. In a case study of 3 partici-
pants, acamprosate was associated with the increased use of 
social communicative language, with content more appropri-
ate to a given discussion; however, this benefit was not ac-
companied by significant improvements in nonverbal aspects 
of communication, such as eye gaze, based on par-
ent/caregiver report or physician interview [71]. A prospec-
tive open-label trial for 10 weeks in children ages 6 to 12 
years with FXS showed treatment response in 9 of the 12 
subjects (75%) in social behavior and inatten-
tion/hyperactivity using multiple standard behavior outcome 
measures. Moreover, the drug was well tolerated with no 
severe or serious adverse effects reported [72]. Acamprosate 
is suggested to be the preferred targeted treatment for those 
with FXS and comorbid alcohol dependence [73]. This 
medication is also currently available clinically.   
2.5. Lovastatin 
 Research has also shown that lovastatin, 3-hydroxy-3-
methylglutaryl-CoA (HMG-CoA) reductase inhibitor used in 
the treatment of hyperlipidemia and hypercholesterolemia, 
inhibits the RAS-MAPK-ERK1/2 activation pathway [74]. 
This drug has also been shown to normalize the excess pro-
tein synthesis and can prevent epileptogenesis in the FMR1 
KO mouse model, which is a functional consequence of in-
creased protein synthesis in FXS [75]. An open-label study 
in 15 participants with FXS over 12 weeks showed signifi-
cant improvement in aberrant behavior as measured by the 
global score of the Aberrant Behavior Checklist-Community 
(ABC-C) and adaptive skills across all three domains [com-
munication, living skills and socialization] of the Vineland 
Adaptive Behavior Scales, Second Edition (VABS-II). Lo-
vastatin was well tolerated with transient and mild adverse 
events [76]. Further clinical trials are being conducted with 
lovastatin with PILI (NCT02642653) and combined treat-
ment of lovastatin with minocycline (LovaMix, 
NCT02680379). Lovastatin is currently available for clinical 
use, but the results of controlled trials are not yet available. 
2.6. Minocycline 
 Minocycline is an antibiotic of the tetracycline class that 
is often used to treat acne. This drug has also been investi-
gated as a treatment for FXS animal models due to its inhibi-
tion of the activity of MMP-9 [77]. FMRP negatively regu-
lates the translation of MMP-9, such that FMRP deficiency 
leads to elevated MMP-9 activity, which alters synaptic plas-
ticity and accounts for some of the cognitive and behavioral 
impairments in FXS. Animal studies in the FMR1 KO mouse 
and in Drosophila have demonstrated that minocycline im-
proved synaptic connections, brain structure, vocalizations, 
and behavior/cognition [77, 78]. These promising preclinical 
data led to clinical studies in patients with FXS. 
 Open-label studies with minocycline involving 19 pa-
tients with FXS ages 13 to 32 years showed significant im-
provements in behavioral outcomes in 4 out of 5 sub-scale 
scores of the ABC-C (irritability, stereotypy, hyperactivity 
and inappropriate speech). Adverse effects documented in 
this study were dizziness, diarrhea and seroconversion to a 
positive antinuclear antibody (ANA) in 2 trial subjects [79]. 
A study to document side effects and potential outcome 
measures for minocycline use for a minimum of 2 weeks was 
also undertaken on 50 patients. In this study, 21 patients 
(39.6%) reported side effects, with gastrointestinal problems 
being the most common (loss of appetite in 16%, gastrointes-
tinal upset in 12%, and diarrhea in 8%); 1 patient had dark-
ening of nails, and a small subset of patients experienced 
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worsening of hyperactivity and moodiness. There were no 
reports of photosensitivity, tooth discoloration, or skin rash. 
Parents reported improvements in language, attention, social 
communication, and anxiety [80]. These two studies 
prompted a randomized double-blind, placebo-controlled 
crossover trial of minocycline in 66 children and adolescents 
ages 3.5 to 16 years with FXS; 55 participants completed 1 
arm while 48 finished both arms of the study. Study partici-
pants received 3 months of minocycline treatment and 3 
months of treatment with placebo with no washout period in 
between treatments. There were significant but modest im-
provements in the Clinical Global Impression-Improvement 
(CGI-I) scale as well as anxiety and mood-related behaviors 
in the Visual Analog Scale (VAS). The majority of adverse 
events were mild except for one patient who had a seizure 
while on the placebo arm [31]. Minocycline is available 
clinically but its use with FXS requires testing of ANA and 
liver function studies at least once per year for safety moni-
toring, and more frequent testing is warranted if a rash de-
velops. 
CONCLUSION 
 Knowledge about FXS and other fragile X-associated 
disorders has grown significantly over the past decade. Tak-
ing into account the progress in the field of FXS, this article 
emphasizes that we are now entering a new era of the phar-
macotherapeutic approach to treatment for patients with 
FXS. Nowadays, there is an increasing number of clinically 
available medications that fit the definition of a targeted 
treatment that can reverse the neurobiological abnormalities 
in genetic disorders as documented by animal models of spe-
cific genetic disorders. Here we reviewed several identified 
targeted treatments that are available clinically and can be 
prescribed for patients with FXS. Many of these medications 
are currently undergoing randomized controlled trials so that 
their safety and efficacy can be documented, but their off-
label clinical use is ongoing and has already generated the 
preliminary positive results described here. Many of these 
medications can also be utilized with other psychotropic 
medications that are not described here because they are not 
considered targeted treatments for FXS but that have instead 
been helpful in treating the comorbid symptoms of FXS [6]. 
Since many pathways and proteins are disrupted in the ab-
sence of FMRP [3], it is likely that a combination of medica-
tions will be beneficial in those with FXS depending on the 
individual constellation of comorbid symptoms. Physicians 
should be encouraged to utilize targeted treatments as they 
become available clinically because they have the potential 
for improving not only behavior but perhaps cognition long 
term, as well. Additionally, there are many new targeted 
treatments under development that are not yet available 
clinically, such as trofinetide, AFQ056, arbaclofen and ga-
boxadol, and these new medications may show efficacy in 
current or future controlled trials. Therefore, clinicians 
should be alert to when these drugs would become available 
for clinical use [4, 8]. At some point in the future, it is possi-
ble that stem cell therapy and gene editing techniques may 
also become available for treatment of FXS. 
 These targeted treatments, with their promising results in 
FXS animal models and clinical settings, emerge as the cor-
nerstone in the pharmacological therapy of FXS. The patho-
physiological mechanisms in FXS can be partially normal-
ized by targeted treatment. Consequently, these new medica-
tions will not only improve the symptoms in individuals with 
FXS but hopefully also increase the level of their independ-
ent functioning in everyday life. For those individuals start-
ing such treatments early in life, long-term follow-up studies 
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